In the fast-paced world of drug development, every investment decision is a balancing act. For Biotech startups, Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) solutions can feel like a “later-stage” priority—something you focus on after you’ve proven clinical efficacy. But in today’s environment, waiting too long can mean missed opportunities with investors, regulators, and payers.
So, when is the right time to make the leap? The answer is often earlier than you think. Your Biotech startup can benefit tremendously from integrating HEOR and RWE as early as the preclinical phase, all the way through phase three.
Utilizing HEOR and RWE early in the drug development lifecycle is critical for startups to showcase value and gain regulatory support and market traction. Plus, investing in HEOR and RWE at key milestones will stretch your investment further.
What is HEOR and RWE?
If you’re unfamiliar with HEOR and RWE, let’s take a moment to level-set on how the industry defines these practices.
HEOR is the discipline that helps evaluate the value of a medical treatment—beyond just whether it works medically. It examines how a therapy affects patient health, quality of life, and the overall cost of care.
In practice, HEOR studies might answer questions like:
- How does this new drug compare to existing treatments in terms of patient outcomes?
- Does it help patients live longer or have a better quality of life?
- Does it reduce healthcare costs by preventing hospitalizations or complications?
By combining clinical results with economic and patient-centered outcomes, HEOR helps companies demonstrate the full value of their product to regulators, payers, and healthcare providers.
Example: An HEOR study evaluating the cost-effectiveness of a drug prevents hospitalizations, yielding annual savings of $5,000 per patient.
HEOR is a framework and a set of methods for assessing the value of healthcare interventions, whereas RWE refers to the data and insights derived from observing how a treatment performs in routine clinical practice. Evidence is drawn from real-world healthcare sources like electronic health records, healthcare claims, and patient registries.
Example: A real-world evidence study showing that a drug reduced ER visits by 25 percent compared to standard care.
Why HEOR and RWE Matter for Startups
Traditionally, HEOR and RWE were seen as tools for post-approval market access. Still, these disciplines are increasingly being brought into earlier phases of development because they provide evidence beyond clinical trials, showcase economic value stories, and offer regulatory support.
While clinical trials are still the gold standard for proving a treatment’s safety and efficacy, companies are increasingly adding RWE as a complement. While clinical trials prove your therapy works in an ideal world, RWE shows how it performs in real-world populations. With RWE, you can gain insights into patient characteristics, disease burden, and treatment gaps earlier, which aids in strategic planning.
Startups are also discovering that RWE provides an economic value story, allowing payers and investors to see how your innovation reduces costs or improves outcomes.
When it comes to regulatory approval, which is necessary to get your therapy to market, agencies like the FDA and EMA are increasingly using RWE to supplement clinical trial data and support accelerated pathways.
RWE During Early Clinical Development
During the preclinical or early clinical phases, you may not need a complete HEOR program yet, but laying the foundation is critical. Early value framing helps shape trial endpoints, comparator arms, and data collection strategies that will matter for both regulators and payers later. By starting HEOR and RWE at this stage, you’ll be able to:
- Define your value proposition from the start.
- Identify the unmet need and potential economic impact.
- Start building your value story based on HEOR and RWE findings.
HEOR and RWE During Late Clinical Development
This is often the sweet spot for serious HEOR and RWE investment. Payers and HTA (Health Technology Assessment) bodies will expect economic and outcomes data at launch. Generating it in parallel with pivotal trials avoids delays. At this stage, you should:
- Conduct burden of illness and cost-effectiveness studies.
- Develop early economic models to guide pricing and reimbursement scenarios.
- Consider RWE feasibility assessments to understand data availability in target geographies.
HEOR and RWE During Pre-Launch Planning
If you’ve reached the pre-launch stage without a robust HEOR/RWE plan, now is your last window to act. Pricing, reimbursement, and formulary placement depend heavily on compelling economic and outcomes evidence. This is your launch fuel. Now is the time to:
- Gather real-world comparator data to contextualize your clinical results.
- Use observational studies or registries to fill evidence gaps.
- Prepare HTA submission dossiers to support global market access.
Conclusion
Startups that delay HEOR and RWE investment often face gaps in evidence that stall payer negotiations, higher costs to retroactively collect missing data, and delayed revenue due to market access barriers.
HEOR and RWE are no longer “nice-to-have” post-launch tools. For Biotech startups, integrating these solutions early and strategically can mean smoother approvals, faster market access, and stronger investor confidence.
Think of HEOR and RWE not as an expense to delay, but as an asset that compounds in value the earlier you start.